About Invus
Invus is a private equity firm founded in 1985. It is primarily based in New York City, United States. As of Jul 2026, Invus is an active investor with a portfolio of 265 companies, comprising 265 funding rounds and 1 acquisition. In the last 12 months, it has participated in 21 funding rounds. The firm primarily invests in companies based in United States and United Kingdom. Its portfolio is spread across a wide range of sectors from Life Sciences to Enterprise Applications. Its latest investment was a $***** Series B round in Osanni on Jun 23, 2026 which also saw participation from Patient Square Capital, Horowitz Group and other investors.
A lot of funds co-invest with Invus, with names like Fidelity Investments sharing a substantial percentage of its portfolio.
Invus has a team of 67 people, including 28 partners.
Key Metrics
Founded Year
1985
Location
New York City, United States
Portfolio Sectors
Portfolio Locations
Acquisition Deals
Invus' Portfolio
Invus has a portfolio of 265 companies. They have invested in a total of 265 companies. Their most recent investment was in Osanni (Series B round) on Jun 23, 2026. Here is the most recent investment by Invus:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Jun 23, 2026 | Series B | 5512 | ||
Jun 10, 2026 | Series D | 4861 | ||
Jun 08, 2026 | Series B | 2872 | ||
Jun 02, 2026 | Series B | 7175 | and 3 others |
Invus has acquired 1 company. Their most recent acquisition was of Ashley Stewart on Apr 01, 2024. Here is the most recent acquisition by Invus:
Acquisition Date | Company | Short Description | Total Funding | Founded Year |
|---|---|---|---|---|
Apr 01, 2024 | Retailer of plus-size women's apparel and accessories | $30.2M | 1991 |
Here is the portfolio snapshot of Invus:
Investments by Year
The maximum number of investments were made in 2021
Portfolio by Location
Companies are primarily in United States and United Kingdom
Portfolio by Sector
Companies are primarily in Life Sciences
Team profile of Invus
Invus has a team of 67 members including 28 Partners and 9 Principals located in United States, France and 2 more locations. Invus' team sits on the board of 4 companies.Here is a list of top team members in Invus:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | |||
Partner | Paris | - | - | |
Partner | France | - | - | |
Partner | United States | - | ||
Partner | - | - | ||
Partner | United States | - | ||
Partner | Paris | - | - | |
Partner | New York | - | - | |
Partner | New York City | - | ||
Partner | New York City | |||
Partner | New York City | - |
Co-investors of Invus
Over the past 41 years, 437 investors have co-invested in Invus's portfolio companies.
- Top Co-investors of Invus: 437 investors entered a company along with Invus. These include investors like Fidelity Investments (17 companies).
Invus News
•
City Therapeutics Secures $99.5M Series B for RNAiVentureburn•Jun 09, 2026•City Therapeutics, NYBC Ventures, Regeneron Ventures, Rock Springs Capital and 6 others
•
Contraline Raises $92.5 Million Series B to Advance NES/T Male Contraceptive DevelopmentVentureburn•Jun 02, 2026•Invus, Contraline, Lumira Ventures, RA Capital Management and 4 others
•
Coultreon Biopharma Secures $125M Series A to Advance Immunology PipelineBioSpace•Apr 28, 2026•Novo Holdings, Forbion, Sofinnova Investments, Finchley Healthcare Ventures and 16 others
•
•
•
CORXEL Announces $287 Million Series D1 Financing for Cardiometabolic PipelineBenzinga•Jan 22, 2026•One Capital Management, RA Capital Management, RTW Investments, CORXEL and 11 others
•
Secretive startup Mirador raises $250M, plans to become immunology powerhouseEndpoints•Jan 11, 2026•Mirador, Fidelity Investments, Blue Owl, Adage Capital Management and 13 others
•
Parabilis gets $305M to conquer 'undruggable' proteins after early successEndpoints•Jan 08, 2026•Parabilis Medicines, Johnson & Johnson, Frazier Life Sciences, Rock Springs Capital and 19 others
•
GenSight Biologics Completes a Fundraising of Nearly €2.9 MillionWebDisclosure•Dec 29, 2025•Invus, Alumni Capital, GenSight Biologics, Heights Capital
•
